Used primarily in the treatment of rare blood disorders such as paroxysmal nocturnal hemoglobinuria (PNH), this antibody prevents the breakdown of red blood cells by inhibiting the complement system. It is also effective in managing atypical hemolytic uremic syndrome (aHUS), where it reduces the risk of blood clots and kidney damage by blocking uncontrolled complement activation. Additionally, it has been applied in generalized myasthenia gravis (gMG) to reduce muscle weakness and improve neuromuscular function by inhibiting complement-mediated damage, and in neuromyelitis optica spectrum disorder (NMOSD) to prevent relapses caused by immune-mediated attacks on the nervous system. Its targeted action makes it a critical therapy in controlling complement-driven autoimmune conditions.